Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (DE:COJ0)
:COJ0
COJ0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.08 - €0.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.31M
Enterprise ValueN/A
Total Cash (Recent Filing)€73.75M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-Date
Jun 13, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,801,197
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.67
Price to Sales (P/S)0.00
P/FCF Ratio-1.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
COJ0 FAQ
What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was €0.08 and its highest was €0.25 in the past 12 months.
What is CombiGene AB’s market cap?
CombiGene AB’s market cap is €4.31M.
When is CombiGene AB’s upcoming earnings report date?
CombiGene AB’s upcoming earnings report date is Aug 22, 2025 which is in 71 days.
How were CombiGene AB’s earnings last quarter?
Currently, no data Available
Is CombiGene AB overvalued?
According to Wall Street analysts CombiGene AB’s price is currently Overvalued.
Does CombiGene AB pay dividends?
CombiGene AB pays a Notavailable dividend of €0.018 which represents an annual dividend yield of N/A. See more information on CombiGene AB dividends here
What is CombiGene AB’s EPS estimate?
CombiGene AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CombiGene AB have?
CombiGene AB has 19,801,197 shares outstanding.
What happened to CombiGene AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CombiGene AB?
Currently, no hedge funds are holding shares in DE:COJ0
Company Description
CombiGene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Technical Analysis
OncoZenge AB
―
Modus Therapeutics Holding AB
―
ExpreS2ion Biotech Holding AB
―
Spago Nanomedical AB
―
Sprint Bioscience AB
―